BUZZ-ASX shares of Mesoblast jump on FDA meeting plans, Phase 3 study update
Reuters
Nov 05
BUZZ-ASX shares of Mesoblast jump on FDA meeting plans, Phase 3 study update
** ASX-listed shares of inflammatory disease drug maker Mesoblast MSB.AX rise as much as 2.3% to A$2.465, their biggest intra-day percentage gain since October 21
** MSB says co will meet with U.S. Food & Drug Administration in early December to discuss data on opioid reduction
** Says co will also discuss cessation from its first Phase 3 study (MSB-DR003) of rexlemestrocel-L in patients with chronic low back pain
** Stock third-biggest percentage gainer in the S&P/ASX 200 Health care sub-index
** Stock currently up 1% at A$2.435
** Stock down 22.3% this year, including the day's move
(Reporting by Roushni Nair in Bengaluru)
((Roushni.nair@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.